・Executive board member; SHVM (https://heartmetabolism.org/). 

・Associate Editorial board member; Frontiers in Cardiovascular Medicine (frontiersin.org/journals/cardiovascular-medicine#)

・Editorial board member;

        Scientific Reports (nature.com/srep/), J Mol Cell Cardiol (jmcc-online.com), 

        Frontiers in Physiology (https://www.frontiersin.org/journals/physiology).

・Fellow; European Society of Cardiology (FESC)

・Fellow; American Heart Association (FAHA)

・Chair; International Society of Heart Research (ISHR) MCI global members  (https://ishrworld.org/)

・Former Leader; U45 International Society of Heart Research (ISHR)- Japanese Section (u45ishr.com)

・ISHR Mid-Career Investigator (MCI) member.

・Organizer;

       SAMURAI (https://samurairesearcher.jimdofree.com/)

       UNIVERSE (https://universe2022.jimdofree.com/)

・PI; A-FiD research consortium, SRD research consortium

・Member of JST FOREST Program ( JST)

・ORCID ID; https://orcid.org/0000-0003-3333-8131

・Loop profile: 490714

・Scopus Author ID: 7202212470

EDUCATION

2006-2010       Doctoral coarse, Chiba university graduate school of medicine (Chiba, Japan)

1996-2002        Chiba University faculty of medicine (Chiba, Japan)

 

WORK EXPERIENCE

2023~                 Director, Department of Cardiovascular Aging, Specially-appointed director, Department of Heart Failure,

                            National Cerebral and Cardiovascular Center (NCVC), Osaka, Japan

2021- 2023         Associate Professor, Department of Cardiovascular Biology and Medicine, 

                             Juntendo University Graduate School of Medicine, Tokyo, Japan

2014-2021          Associate Professor, Department of Cardiovascular Biology and Medicine

                             Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Japan

2013-2014         Boston University School of Medicine, Research Instructor of Medicine

2012-2013         Boston University School of Medicine, Whitaker Cardiovascular Institute,  Molecular Cardiology, postdoc

2010-2012         Chiba University Hospital Department of Cardiology, postdoctoral fellow

2004-2006          Sakakibara Heart Institute, Cardiovascular Internal Medicine, specialist trainee 

2002-2004         National Center for Global Health and Medicine, foundation house officer

 

QUALIFICATIONS

1.     Fellow of the Japanese Society of Internal Medicine (FJSIM), 2016

2.     Doctor of Philosophy, 2010

3.     Cardiovascular Specialist of Japanese Circulation Society, 2009

4.     Board Certified Member of the Japanese Society of Internal Medicine, 2005

 

EDITORIAL BOARD MEMBERSHIP etc.

1.     Associate Editorial board member; Frontiers in Cardiovascular Medicine

2.     Editorial board member; J Mol Cell Cardiol

3.     Editorial board member; Scientific Reports

4.     International reviewer member; Diabetes and Metabolism Journal (Official journal of the Korean Diabetes Association(KDA))

5.     Fellow; European Society of Cardiology (FESC)

6.     Fellow; American Heart Association (FAHA)

7.     Chair of ISHR-MCI global members

8.     Former Leader; U45 International Society of Heart Research (ISHR) Japanese section (https://www.u45ishr.com/)

 

PROFESSIONAL SOCIETIES

1.     American Heart Association

2.     European Society of Cardiology, Professional Member

3.     European Society of Cardiology, Working Group on Cellular Biology of the Heart

4.     European Society of Cardiology, Heart Failure Association regular membership

5.     Japanese Circulation Society

6.     Honorary member, Korean Society of Cardiology 2016.4.16-

7.     The Japanese Society of Internal Medicine

8.     International Society for Heart Research Japanese Section

9.     Society of Cardiovascular Endocrinology and Metabolism

10.  The Japan Geriatrics Society

11.  The Japanese Society of Hypertension

12.  The Japanese Heart Failure Society

13.  Japan Society of the Study of Obesity

14.  Japanese Society for Circulation Research

15.  The Molecular Biology Society of Japan

16.  Japanese Society of Anti-Aging Medicine

17.  Japanese College of Cardiology

18.  The Japanese Vascular Biology and Medicine Organization

19.  The Japanese Onco-Cardiology Society

 

1.     Councilor; The Japanese Vascular Biology and Medicine Organization

2.     Councilor; Society of Cerebral-Cardio-Vascular Anti-Aging

3.     Councilor; The Japanese Onco-Cardiology Society

4.     Councilor; The Society of Cardiovascular Endocrinology and Metabolism

5.     Councilor; Japanese Society of Anti-Aging Medicine

6.     Councilor; The NO society of Japan

7.     Councilor; Kantokoushinetsu Regional Office of the Japanese Circulation Society

ACADEMIC HONORS

2023 Appreciation Award、Korean Society for Biochemistry and Molecular Biology (KSBMB), Bomum Symposium

2020 Catalyst Award, U.S. National Academy of Medicine (USA)

2020 President’s Award, Niigata University, Japan

2016 Jokichi Takamine Young Investigator Award, Annual Scientific Session of the Society of Cardiovascular Endocrinology and Metabolism

2014 First Place, Young Investigator Competition of the 58th Annual Scientific Meeting. The Korean Society of Cardiology. Nov 28, 2014, Republic of Korea.

2014 President’s Award, Niigata University, Japan

2013 Best of the Day, Poster Award, XXI ISHR World Congress, 2013, July, USA 

2013 Travel Award for the ISHR XXI World Congress, San Diego California, USA

2012 Winner, 2012 Melvin L. Marcus Young Investigator Award in Cardiovascular Sciences,

    American Heart Association Scientific Sessions 2012, Los Angeles, USA

2012 Young Investigators Award, The 49th Annual Meeting of the Japanese Society of Molecular Medicine, Kyoto, Japan

2011 Outstanding Best Presenter Award, 12th US-Japan-Asia Dialogue on Cardiovascular Disease 

    and Young Investigator Competition, Tokyo, Japan

2011 Chiba Medical Society Young Investigator Award, Japan

2011 Exceptional Poster Award, Miyazaki Science Camp, Japan

2011 Award for Excellence, 4th Frontier of Cardiovascular Disease and Metabolic Syndrome Research, Japan

2010 Young Investigators Award, The 27th Annual Scientific Session of the International Society for Heart Research, Japanese Division, Kyoto, Japan

2010 Young investigators Award, The 14th Annual Scientific Session of the Society of Cardiovascular Endocrinology and Metabolism, Nara, Japan

2010 Dean’s Award, Chiba University Graduate School of Medicine and Pharmaceutical Sciences, Japan

2010 President’s Award, Chiba University, Japan

2009 Outstanding achievement award (Prof. Issei Komuro) , Japan

2009 Young Investigator Award (highest award), 2nd Cardiovascular Aging and Metabolic Syndrome Symposium on the      Pathophysiology of Cancer, Japan

 

PUBLICATIONS

・  Katsuumi G*, Shimizu I*, Suda M, Yoshida Y, Furihata T,  Joki Y, Hsiao CL, Jiaqi L, Fujiki S, Abe M, Sugimoto M, Soga T & Minamino T. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nature Aging. 2024 May 30,

 *Co-first author.

・  Shimizu I, Exploration of new therapies for heart failure targeting age-related mechanisms. Circ J. 2023.

・  Shimizu I. “Reproducibility and Reporting of Negative Results in Cardiovascular Research” from the perspective of mid-career investigator. J Mol Cell Cardiol Plus. (in press) 

・Furuuchi R*, Shimizu I*,**, Yoshida Y, Katsuumi G, Suda M, Kubota Y, Walsh K, Minamino T. Endothelial SIRT-1 has critical role for the maintenance of capillarization in brown adipose tissue. iScience. 2022 Nov18, 25, 105424. *Co-first author, **Co-corresponding author

・Yoshida Y*, Shimizu I*,**, Shimada A, Nakahara K, Yanagisawa S, Kubo M, Fukuda S, Ishii C,

Yamamoto H, Ishikawa T, Kano K, Aoki J, Hayashi Y, Ikegami R, Katsuumi G, Suda M, Ozaki K, Kashimura T, Izumi D, Yoshida Y, Okuda S, Ohta S, Okamoto S, Minokoshi Y, Oda K, Sasaoka T, Abe M, Sakimura K, Kubota Y, Yoshimura N, Kajimura S, Zuriaga M, Walsh K, Soga T** and Minamino T**. Brown adipose tissue dysfunction promotes heart failure via a trimethylamine N-oxide-dependent mechanism. Sci Rep. 2022 Sep 1;12(1):14883. *Co-first author, **Co-corresponding author

・Hayashi Y*, Shimizu I*,**, Yoshida Y*, Ikegami R, Suda M, Katsuumi G, Nakao M, Fujiki S, Abe M, Sakimura K, Okuda S, Hayano T, Walsh K, Jespersen NJ, Nielsen S, Scheele C, Minamino T**. Coagulation factors promote brown adipose tissue dysfunction and abnormal systemic metabolism in obesity. iScience. 2022 Jun 7;25(7):104547. *Co-first author, **Co-corresponding

・Suda M*, Shimizu I*, Katsuumi G, Yoshida Y, Matsumoto N, Yoshida Y, Katayama A, Wada J, Seki M, Suzuki Y, Okuda S, Ozaki K, Matsui M, Minamino T. Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells. Sci Rep. 2022, April 20, 6522. *Co-first author.

・Yoshida Y*, Shimizu I*,**, Minamino T*. Capillaries as a therapeutic target for heart failure. J Atheroscler Thromb. 1;29(7):971-988. April1, 2022. *Joint senior authors, **Corresponding

・Yoshida Y*, Shimizu I*, Yung Ting Hsiao*, Hayashi Y, Suda M, Katsuumi G, Ikegami R, Nakao M, Sakai R, Seki M, Suzuki Y, Okuda S, Soga T, Minamino T. Differing impact of phosphoglycerate mutase 1-deficiency on brown and white adipose tissue. iScience. 2022 Apr 18;25(5):104268 *Co-first author

・Park N, Marquez J, Pham T, Ko TH, Youm JB, Kim M, Choi SH, Moon J, Flores J, Ko K, Rhee BD, Shimizu I, Minamino T, Ha JD, Hwang JY, Yang SJ, Park CS, Kim HK and Han J. Cereblon contributes to cardiac dysfunction by degrading Cav1.2α. European Heart Journal. 2022, Feb; 22.

・Hsiao Y T*, Shimizu I*,**, Yoshida Y, Minamino T**. Role of circulating molecules in age-related cardiovascular and metabolic disorders. Inflammation and regeneration. 42(1):2, Jan1, 2022. *Co-first author, **Co-corresponding author

・Nakao M, Shimizu I*,**, Katsuumi G, Yoshida Y, Suda M, Hayashi Y, Ikegami R, Hsiao Yung Ting, Okuda S, Soga T, Minamino T**. Empagliflozin Maintains Capillarization and Improves Cardiac Function in a Murine Model of Left Ventricular Pressure Overload. Sci Rep. 11, Article number: 18384 (2021). *Co-first author, **Co-corresponding

・Cho K, Ushiki T, Ishiguro H Tamura S, Araki M, Suwabe T, Katagiri T, Ohashi R, Ajioka Y, Shimizu I, Okuda S, Masuko M, Nakagawa Y, Hirai H, Alexander W, Shimano H, Sone H. Altered Microbiota by a High-Fat Diet Accelerates Lethal Myeloid Hematopoiesis Associated with Systemic Socs3 Deficiency. iScience. (in press).

・Suda M*, Shimizu I*, Katsuumi G, Yoshida Y, Matsumoto N, Hayashi Y, Ikegami R Yoshida Y, Mikawa R, Katayama A, Wada J, Seki M, Suzuki Y, Iwama A, Nakagami H, Nagasawa A, Morishita R, Sugimoto M, Okuda S, Tsuchida M, Ozaki K, Matsui M, Minamino T. Senolytic vaccination improves pathological aging. Nature aging. 2021, Dec; 10. *Co-first author

・Hsiao YT*, Shimizu I*,**, Wakasugi T, Jiao S, Watanabe T, Yoshida Y, Ikegami R, Hayashi Y, Suda M, Katsuumi G, Nakao M, Ozawa T, Kashimura T, Ozaki K, Hanawa H, Minamino T**. Cardiac Mitofusin-1 is Reduced in Non-responding Patients with Idiopathic Dilated Cardiomyopathy. Sci Rep. Mar24; 11(1):6722, 2021.*Co-first author, **Co-corresponding author

・Kim HK, Ko T, Song I, Jeong Y, Heo HJ, Jeong S, Kim M, Park NM, Seo DY, Kha PT, Kim SW, Lee SR, Cho SW, Won JC, Youm JB, Ko K, Rhee B, Kim N, Cho KI, Shimizu I, Minamino T, Ha NC, Park Y, Nilius B, Han J. BH4 activates CaMKK2 and rescues the cardiomyopathic phenotype in rodent models of diabetes. Life Science Alliance. 2020 Jul 22;3(9):e201900619.

・Shimizu I*, Minamino T*. Cellular senescence in arterial diseases. Journal of lipid and atherosclerosis. 9(1):79-91, 2020. *Co-corresponding author

・Fujiki S, Iijima K, Okabe M, Niwano S, Tsujita K, Naito S, Ando K, Kusano K, Kato R, Nitta J, Miura T, Mitsuhashi T, Kario K, Kondo Y, Ieda M, Hagiwara N, Murohara T, Takahashi K, Tomita H, Takeishi Y, Anzai T, Simizu W, Watanabe M, Morino Y, Kato T, Tada H, Nakagawa Y, Yano M, Maemura K, Kimura T, Yoshida H, Ota K, Tanaka T, Node K, Aizawa Y, Shimizu I, Izumi D, Ozaki K, and Minamino T. On behalf of the EMPA-ICD investigators. Placebo-controlled, double-blind study of empagliflozin (EMPA) and implantable cardioverter-defibrillator (EMPA-ICD) in patients with type 2 diabetes (T2DM): rationale and design. Diabetes Ther. 2020 Nov;11(11):2739-2755.

・Fujiki S, Watanabe H, Obata H, Suda M, Mitsuma W, Tomii A, Sakai K, Uehara A, Shimizu I, Kashimura T, Ozaki K, Minamino M. Association of adipokines with frailty in heart failure. Acta Biomed. 2021 Jul 1;92(3):e2021195. 

・Kim HK, Jeon J, Song IS, Heo HJ, Jeong SH, Long LT, Thu VT, Ko TH, Kim M, Kim N, Lee SR, Yang JS, Kang MS, Ahn JM, Cho JY, Ko KS, Rhee BD, Nilius B, Ha NC, Shimizu I, Minamino T, Cho KI, Park YS, Kim S, Han J. Tetrahydrobiopterin enhances mitochondrial biogenesis and cardiac contractility via stimulation of PGC1α signaling. Biochim Biophys Acta Mol Basis Dis. 2019 Aug2; S0925-4439(19)30241-8

・Shimizu I*, Minamino T. Cellular senescence in cardiac diseases. J Cardiol. 2019 Jun 12; S0914-5087(19)30128-5 *Co-corresponding author

・Yoshida Y*, Shimizu I*, Hayashi Y, Ikegami R, Suda M, Katsuumi G, Wakasugi T, Nakao M, Nakagmi H, Morishita R, Minamino T. Peptide vaccine for semaphorin3E ameliorates systemic glucose intolerance in mice with dietary obesity. Sci Rep. 2019 Mar7; 9(1)3858 *Co-first author

・Yokoyama M*, Shimizu I*, Nagasawa A, Yoshida Y, Katsuumi G, Wakasugi T, Hayashi Y, Ikegami R, Suda M, Ota Y, Okada S, Fruttiger M, Kobayashi Y, Tsuchida M, Kubota Y, Minamino T. p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia. J Mol Cell Cardiol. 129:105-117, 2019. *Co-first author

・Wakasugi T*, Shimizu I*, Yoshida Y, Hayashi Y, Ikegami R, Suda M, Katsuumi G, Nakao M, Hoyano M Kashimura T, Nakamura K, Ito H, Nojiri T, Soga T, Minamino T. Role of smooth muscle cell p53 in pulmonary arterial hypertension. PLOS One. (IF 3.24) (CI8), 14(2)e0212889, 2019. *Co-first author

・Ikegami R*, Shimizu I*,**, Sato T*, Yoshida Y, Hayashi Y, Suda M, Katsuumi G, Li J, Wakasugi T, Minokoshi Y, Okamoto S, Hinoi E, Nielsen S, Jespersen N, Scheele C, Soga T, Minamino T**. Gamma-aminobutyric acid signaling in brown adipose tissue promotes systemic metabolic dysfunction in obesity. *Co-first author, **Co-corresponding author Cell Rep. 24(11):2827-28372018

・Furuuchi R*, Shimizu I*, Yoshida Y, Hayashi Y, Ikegami R, Suda M, Katsuumi G, Wakasugi T, Nakao M, Minamino T. Boysenberry polyphenol inhibits endothelial dysfunction and improves vascular health. PLOS One. 13(8):e0202051, 2018. *Co-first author

・Kayamori H, Shimizu I, Yoshida Y, Hayashi Y, Suda M, Ikegami R, Katsuumi G, Wakasugi T, Minamino T. Amlodipine inhibits vascular cell senescence and protects against atherogenesis through the mechanism independent of calcium channel blockade. Int Heart J. 2018 May 30;59(3):607-613 

・Katsuumi G*, Shimizu I*, Yoshida Y, Minamino T. Vascular senescence in cardiovascular and metabolic diseases. Front Cardiovasc Med. 05 March 2018 https://doi.org/10.3389/fcvm.2018.00018. *Co-first author

・Ikegami R*, Shimizu I*, Yoshida Y, Minamino T. Metabolomic analysis in heart failure. Circ J. 2017 ;82(1):10-16 *Co-first author

・Katsuumi G*, Shimizu I*,**, Yoshida Y, Minamino T**. Inflammation and regeneration. 2016 Aug 36;16. The pathological role of vascular aging in cardio-metabolic disorder. *Co-first author, **Co-corresponding author

・Suda M*, Shimizu I*, Yoshida Y, Minamino T. Peripheral blood mononuclear cells for limb ischemia. Therapeutic Angiogenesis. (Springer publication). p25-43, 2017, *Co-first author

・Yoshida Y*, Shimizu I*,**, Minamino T**. Diabetes and adipocyte dysfunction. Diabetes and Aging-related Complications, 69-84 (Springer publication). *Co-first author, **Co-corresponding author

・Suda M*, Shimizu I*, Yoshida Y, Hayashi Y, Ikegami R, Katsuumi G, Wakasugi T, Yoshida Y, Okuda S, Soga T, Minamino T. Inhibition of Dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway. *Co-first author PLOS One. 2017 Aug 3; 12(8), e0182422.

・Kinoshita D, Nagasawa A, Shimizu I, Ito T, Yoshida Y, Tsuchida M, Iwama A, Hayano T and Tohru Minamino. Progerin impairs vascular smooth muscle cell growth via the DNA damage response pathway. Oncotarget. 2017 May 23;8(21):34045-34056 

・Katsuumi G*, Shimizu I*,**, Yoshida Y, Minamino T**. Inflammation and regeneration. 2016 Aug 36;16. The pathological role of vascular aging in cardio-metabolic disorder. *Co-first author, **Co-corresponding author

・Shimizu I*, Minamino T*. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016 Jun 2;97:245-262*Co-corresponding author

・Maruyama S, Nakamura K, Papanicolaou N.K., Shimizu I, Sano S, Asaumi Y, van den Hoff M.J., Ouchi N, Recchia A.F., Walsh K. EMBO Mol Med. 2016 Aug 1; 8(8):949-66. Follistatin-like 1 is an endogenous regulator of cardiac fibroblast activation that protects the heart from post-infarct rupture.

・Shimizu I, Yoshida Y, Minamino T. Hypertens Res. 2016 Feb 18, A role for circadian clock in metabolic disease.  

・Nakamura K, Sano S, Fuster J, Kikuchi R, Shimizu I, Ohshima K, Katanasaka Y, Ouchi N, and Walsh K. J Biol Chem. 2015 Feb 5;291(6):2566-75 Sfrp5 diminishes cardiac inflammation and protects the heart from ischemia-reperfusion injury.

・Shimizu I, Yoshida Y, Minamino T. Diabetes. 2015 (Commentary) Dec;64(12):3984-6. Maintenance of subcutaneous fat homeostasis improves systemic metabolic dysfunction in obesity.

・Nakagomi A, Okada S, Yokoyama M, Yoshida Y, Shimizu I, Miki T, Kobayashi Y, and Minamino T. Aging and Mechanism of Disease. (Nature publishing group) 2015 October, Role of the central nervous system and adipose tissue BDNF/TrkB axes in metabolic regulation. 

・Yoshida Y*, Shimizu I*, Minamino T. Inflammation and regeneration. 2015 September, The pathological role of adipose tissue aging in the progression of systemic insulin resistance. *Co-first author

・Yoshida Y*, Shimizu I*, Katsuumi G*, Suda M, Hayashi Y, Minamino T. J Mol Cell Cardiol. 2015 June 85:183-198. p53-induced inflammation exacerbates cardiac dysfunction during pressure overload. *Co-first author

・Shimizu I*, Yoshida Y, Minamino T*. Int Heart J. 2015 May 13;56(3):255-9. Pathological role of adipose tissue dysfunction in cardio-metabolic disorders. *Co-corresponding author

・Shimizu I*, Walsh K. Curr Obes Rep. 2015 June 4;(2):224-229. Whitening of brown fat and implications for weight management in obesity. *Corresponding author

・Shimizu I, Yoshida Y, Suda M, Minamino T. Cell Metab. 2014 Dec 2;20(6):967-977. DNA damage response and metabolic disease.

・Suzuki H, Kayama Y, Sakamoto M, Iuchi H, Shimizu I, Yoshino T, Katoh D, Nagoshi T , Tojo K, Minamino T, Yoshimura M, Utsunomiya K. Diabetes. 2015 Feb;64(2):618-30. Arachidonate 12/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of Diabetic Cardiomyopathy

・Kikuchi R, Nakamura K, Maclauchlan S, Ngo D, Shimizu I, Fuster J, Katanasaka Y, Yoshida S, Qiu Y, Yamaguchi T, Matsushita T, Murohara T, Gokce N, Bates D, Hamburg N, Walsh K. Nat Med. 2014 Dec;20(12):1464-71. An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease.

・Yoshida Y, Hayashi Y, Suda M, Tateno K, Okada S, Moriya J, Yokoyama M, Nojima A, Yamashita M, Kobayashi Y, Shimizu I, Minamino T. PLOS One. 2014 Jun 20;9(6). Notch Signaling Regulates the Lifespan of Vascular Endothelial Cells via a p16-Dependent Pathway. 

・Yokoyama M, Okada S, Nakagomi A, Moriya J, Shimizu I, Nojima A, Yoshida Y, Ichimiya H, Kamimura N, Kobayashi Y, Ohta S, Fruttiger M, Lozano G, Minamino T. Cell Rep. 2014 Jun12;7(5):1691-703. Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. 

・Shimizu I, Tamar A, Kikuchi R, Shimizu A, Papanicolaou K, Maclauchlan S, Maruyama S, Walsh K.  J Clin Invest. 2014; May;124(5):2099-112. Vascular rarefaction mediates whitening of brown fat in obesity. 

・Shimizu I, Yoshida Y, Moriya J, Nojima A, Uemura A, Kobayashi Y, Minamino T. Cell Metab. 2013 Oct1;18(4):491-504.Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity. (Featured article)

・Nojima A, Yamashita M, Yoshida Y, Shimizu I, Ichimiya H, Kamimura N, Kobayashi Y, Ohta S, Ishii Naoaki, Minamino T. PLOS One. 2013 Jul; 30;8(7). Haploinsufficiency of Akt1 prolongs the lifespan of mice. 

・Shimizu I, Walsh K. J Mol Cell Cardiol. 2013 Jun;59:176-8. Vascular remodeling mediated by Angptl2 produced from perivascular adipose tissue. 

・Shimizu I, Yoshida Y, Katsuno T, Minamino T. Microbes and Infection. 2013; 1:11-7. Adipose tissue inflammation in diabetes and heart failure.

・Tomita K, Teratani T, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K, Nishiyama K, Mataki N, Irie R, Minamino T, Okada Y, Kurihara C, Ebinuma H, Saito H, Shimizu I, Yoshida Y, Hokari R, Sugiyama K, Hatsuse K, Yamamoto J, Kanai T, Miura S, Hibi T. J Hepatol. 2012; 57, 837-843. P53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice.

・Naito AT, Sumida T, Nomura S, Liu ML, Higo T, Nakagawa A, Okada K, Sakai T, Hashimoto A, Hara Y, Shimizu I, Zhu W, Toko H, Katada A, Akazawa H, Oka T, Lee JK, Minamino T, Nagai T, Walsh K, Kikuchi A, Matsumoto M, Botto M, Shiojima I, Komuro I. Cell. 2012; 149: 1298-313. Complement C1q Activates Canonical Wnt Signaling and Promotes Aging-Related Phenotypes.

・Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I, Nojima A, Ito T, Yoshida Y, Kobayashi Y, Katagiri H, Minamino T, Komuro I. Arterioscler Thromb Vasc Biol. 2012; 8: 1902-9.  Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway.

・Shimizu I, Yoshida Y, Katsuno T, Tateno K, Okada S, Moriya J, Yokoyama M, Nojima A, Ito T, Zechner R, Komuro I, Kobayashi Y, Minamino T. Cell Metab. 2012; 15:51-64. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. (Featured article)

・Yasuda N, Akazawa H, Ito K, Shimizu I, Kudo-Sakamoto Y, Yabumoto C, Yano M, Yamamoto R, Ozasa Y, Minamino T, Naito AT, Oka T, Shiojima I, Tamura K, Umemura S, Nemer M, Komuro I. Hypertension. 2012; 59: 627-33. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice.

・Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh G, Akazawa H, Shiojima I, Kahn C, Abel E, & Komuro I. J Clin Invest. 2010;120:1506-1514. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. 

・Moriya J, Minamino T, Tateno K, Okada S, Akiyoshi U. Shimizu I, Yokoyama M, Nojima A, Henderson CE, Okada M, Koga H, Komuro I. Circ Res. 2010; 106:391-8. Inhibition of Semaphorin As a Novel Strategy for Therapeutic Angiogenesis.

・Minamino T*, Orimo M*, Shimizu I*, Kunieda T, Yokoyama M, Ito T, Nojima A, Nabetani A, Oike Y, Matsubara H, Ishikawa F, Komuro I. Nat Med. 2009; 15:1082-7. A crucial role for adipose tissue p53 in the regulation of insulin resistance. *Co-first author

・Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, Okada S, Tateno K, Moriya J, Yokoyama M, Nojima A, Yoshimura M, Egashira K, Aburatani H and Komuro I. J. Exp. Med. 2009; 206:1565-74. Cardiac 12/15-lipoxygenase-induced inflammation is involved in heart failure. 

・Shimizu I, Iguchi N, Watanabe H, Umemura J, Tobaru T, Asano R, Misu K, Nagayama M, Aikawa M Funabashi N, Komuro I, Sumiyoshi T. Int J Cardiol. 2010; 142:224-9. Delayed enhancement cardiovascular magnetic resonance as a novel technique to predict cardiac events in dilated cardiomyopathy patients.

・Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I. Nature. 2007; 446:444-8. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.

INVITED LECTURES AND PRESENTATIONS   -International- 

・Shimizu I. Cellular senescence as a therapeutic target for age-related disorders. The 10th Federation of the Asian and Oceanian Physiological Scientific Congress (FAOPS2023), EXCO, Daeugu, Korea, 2nd, November, 2023.

・Shimizu I. Targeting cell-senescence as a therapy for age-related disorders. Korean Society for Biochemistry and Molecular Biology (KSBMB2023), Fukuoka, Japan, 26th, October, 2023.

・Shimizu I. Role of brown adipose tissue in cardiovascular-metabolic disorders. The 12th International Congress on Lipid & Atherosclerosis with Asia-Australia Vascular Biology Meeting (ICoLA2023), Conrad Seoul, Korea, 15th, September, 2023.

・Shimizu I. Developing next-generation therapy for Age-related Fibrotic Disorders targeting secreted type pro-fibrotic protein (A-FiD research consortium study). The 12st Asia Partnership Conference of Pharmaceutical Associations. 18th April, 2023.

・Shimizu I. Brown adipose tissue as a therapeutic target for age-related diseases. CMARS symposium. University of Indonesia (online).

・Shimizu I. Society for Heart and Vascular Metabolism (SHVM), Therapies targeting age-related mechanisms16-19 October, 2022, Korea, Seoul.

・Shimizu I. Targeting cell senescence as a therapy for age-related disorders. Metabolic Disorder, Cardiovascular & Aging Research Cluster IMERI, 22 March, 2022, Jakarta, Indonesia (online).

・Shimizu I. The 6th International Conference and Exhibition on the Indonesian Medical Education and Research Institute. Therapy for cardiovascular diseases targeting cellular senescence. Exploration of Next Generation Therapies for Cardiovascular Metabolic Disorders. 11th November, 2021, Indonesia University, Indonesia (Online).

・Shimizu I. The 6th International Conference and Exhibition on the Indonesian Medical Education and Research Institute. Therapy for cardiovascular diseases targeting cellular senescence. 6th November, 2021, Indonesia University, Indonesia (Online).

・Shimizu I. 2021 International Conference of the Korean Society for Molecular and Cellular Biology. Pathogenic role of a senometabolite in cardiovascular diseases. 3rd November, 2021, Korea (Online).

・Shimizu I. Pathological roles of senocules in sync-aging and cardiovascular disorders. International Symposium on Atherosclerosis. 25th October 2021, Korea (Online).

・Shimizu I. Maintenance of mitochondrial health becomes a therapy for heart failure. The 65th Annual Scientific Meeting of The Korean Society of Cardiology. 18th October 2021, Korea (Online).

・Shimizu I. Pathological roles of senocules in sync-aging and cardiovascular disorders. Korean Society for Mitochondrial Research and Medicine (KSMRM). 25th August, 2021, Korea (Online).

・Shimizu I. Pathogenic role of "senocules" in age-related disorders. The 51st NIPS International Symposium, MIRACLES, in Cardiovascular Physiology. 25th December, 2020, Fukuoka(Online), Japan

・Shimizu I. Invited Lecture, Pathogenic role of senocules in age-related disorders. Basic Cardiovascular Sciences (BCVS) 2020 Scientific Sessions, 29th July, 2020, Chicago, USA.

・Shimizu I. Senometabolite promotes pathologies in cardiovascular disorders.“Think aging” makes “Sync aging”.The 50th NIPS International Symposium, MIRACLES, in Cardiovascular Physiology. 5th December, 2019, Aichi, Japan

・Shimizu I. Invited Lecture, Roles of aging signaling in cardiovascular-metabolic disorders. Department Pharmacology of Faculty of Medicine Universitas Indonesia (FMUI), 4th November, 2019, Jakarta, Indonesia.

・Shimizu I. Invited talk, Big data analysis for development of anti-aging medicine, Senolytic drug as a novel candidate for next anti-aging medicine. International Conference and Exhibition on Indonesian Medical Education and Research Institute (ICE ON IMERI), 4th November, 2019, IMERI building, Jakarta, Indonesia.

・Shimizu I. Invited Lecture, Pathogenic role of senometabolites in age-related disorders “Think aging” makes “Sync aging”.National Cardiovascular Center Harapan Kita, 5th November, 2019, Jakarta, Indonesia.

・Shimizu I. Disoriented choline metabolism promotes pathologies in the failing heart. The 62nd Annual Scientific Meeting of The Korean Society of Cardiology, 2018, Oct11, Seoul, Korea.

・Shimizu I. 23rd Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP). May 27, 2018. The Ritz-Carlton, Kyoto. The pathologiacl role of brown adipose tissue dysfunction in cardio-metabolic disorders. 

・Shimizu I. KORUS Symposium 2017. June 28-29, Busan National Science Museum, Busan, Korea.Semaphorin3E is a novel therapeutic target for unhealthy obesity and diabetes. 

・Shimizu I. Symposium, Korean Society for Biochemistry and Molecular Biology (KSBMB) International Conference 2017. May 19, Busan, Korea. The pathological roles of brown adipose-tissue dysfunction in age related disorders.

・Shimizu I. Symposium, Conference on translational and therapeutic perspective of brown adipose, May2-4, Scandic Hotel, Copenhagen 2017. The pathological roles of brown adipose-tissue dysfunction in heart failure, obesity and diabetes.

・Shimizu I. Symposium, 2017 Annual Spring Scientific Conference of the KSC in conjunction with KSIC, KSE, KSLA, and KHRS. April 21-22, 2017, HICO, Gyeongju, Korea. Aging signaling promotes pathologies in heart failure.

・Shimizu I. Invited lecture, Inje University, 2016, December 23, Busan, Korea, CMDC(Cardiovascular Metabolic Disease Center) Symposium. Fat dysfunction promotes pathologies in heart failure, obesity and diabetes.

・Shimizu I. Symposium, The 9th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide (NO2016). 2016, May22, Sendai, Japan. The pathological role of adipose dysfunction in heart failure and obesity.

・Shimizu I. 2016 Annual Meeting of Taiwan Society of Cardiology, May 13-15, 2016, Taipei, Taiwan.

・Shimizu I. Symposium, Annual Spring Scientific Conference of the Korean Society of Cardiology in conjunction with KSIC, KSE, and KSLA & The 8th Asian Pacific Congress of Heart failure, 2016, April 15-16, Gyeongju, Korea. The role of adipose dysfunction in heart failure and obesity.

・Shimizu I. Invited lecture, Inje University, 2016, April14, Busan, Korea. The pathological role of a coagulation factor in promoting brown adipose tissue dysfunction and systemic metabolic disorder in obesity.

・Shimizu I. Seminar, 2016, February 11, Rigshospitalet(Copenhagen University Hospital), Copenhagen, Denmark. Aging signaling promotes pathologies in cardio-metabolic disorders.

・Shimizu I. Symposium, Annual Summer Symposium of the Basic Science study group, branch of the Korean Society of Cardiology, 2015, August 21-22, Osong, Korea. The pathological role of aging signaling in cardio-metabolic disorders.

・Shimizu I. Symposium, 28th Spring Congress of Korean Diabetes Association, 2015, May7-9, Gwangju, Korea. The pathological role of aging signaling in heart failure.

・Shimizu I. Invited lecture, Inje University, 2015, May6, Busan, Korea. The pathological role of adipose tissue dysfunction in cardio-metabolic disorders. 

・Shimizu I. The 58th Annual Scientific Meeting of The Korean Society of Cardiology, 2014, Nov28, Goyang, Korea. Capillary rarefaction mediates whitening of brown fat and contributes to insulin resistance in obesity. 

・Shimizu I. Symposium, American Diabetes Association 73rd Scientific Sessions, Chicago, June21, 2013, Insulin resistance and cardiovascular diseases- A common pathophysiologic link through inflammation?